Encapsulation of cucurbitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage

Bakar‐Ates, Filiz; Ozkan, Erva; Sengel-Türk, Ceyda Tuba

doi:10.1016/j.ijpharm.2020.119565

Cited by 31 publications

(14 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bakar-Ates et al and Tang et al used lipid polymer hybrids and micelles to load CuB, which resulted in enhanced cytotoxicity toward MDA-MB-231 and HepG2 cells, respectively. 35,36 However, the IC 50 values of CDNVs in our study were even lower than theirs (14.75 μM for a CuB-lipid polymer hybrid with MDA-MB-231 cells and 76.95 nM for CuB-micelles with HepG-2 cells), suggesting that anticancer efficacy of CuB may be greater with CDNVs than artificially prepared vesicles. Furthermore, unlike CuB-lipid polymer hybrids and CuB-micelles that require extra CuB extraction and loading steps, simpler preparation makes production of CDNVs more feasible for mass manufacture.…”

Section: Anticancer Effects Of Cdnvs In Vitrocontrasting

confidence: 72%

“…These results demonstrated that CDNVs are a natural nanocarrier of CuB. Without the need of complex encapsulating procedures for CuB in synthetic and artificial nanocarriers, 35,36 CDNVs serve as both a nanocarrier and a resource of CuB to improve the bioavailability and thereby a better anticancer effect of CuB without the risk of the potential toxicity from engineered nanoparticles.…”

Section: Hplc and Lc-ms For Cub Analysismentioning

confidence: 88%

“…[30][31][32][33] However, satisfactory anticancer activity often requires a large dose of CuB because of its low solubility and bioavailability. 34,35 To overcome this limitation, Bakar-Ates et al and Tang et al utilized nanocarriers, lipid polymer hybrid nanocarriers and nanomicelles, to load CuB, and both exhibited greater cytotoxicity than free CuB. 35,36 But the limitations of synthetic nanocarriers, like complex preparation and potential in-vivo toxicity, limit their use as mentioned above.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Cucumber-Derived Nanovesicles Containing Cucurbitacin B for Non-Small Cell Lung Cancer Therapy

Chen¹,

Ma²,

Shi³

et al. 2022

IJN

View full text Add to dashboard Cite

Purpose In recent years, a variety of nanoparticles with excellent anticancer and delivery properties have emerged for cancer therapy. However, potential toxicity, high production cost and complex preparation procedures have been obstacles to their use in biomedicine. Here, we obtained cucumber-derived nanovesicles (CDNVs) at high yield and low cost by simple juicing and ultracentrifugation. The anticancer effects of CDNVs were evaluated in vitro and in vivo. Methods Transmission electron microscope, nanoparticle tracking analysis and laser particle size analysis were used to characterize the morphology, diameter and zeta potential of CDNVs, respectively. The anticancer effects of CDNVs in vitro were evaluated by MTT and apoptosis assays. The mechanism was further explored by measuring the protein levels of signal transducer and activator of transcription 3 pathway, reactive oxygen species, cell cycle distribution and caspase activity. In-vivo anticancer efficacy was evaluated by measuring tumor volume and weight of mice in three different treatment groups (CDNVs, cucurbitacin B and PBS). Results CDNVs inhibited proliferation of human non-small cell lung cancer cells by suppressing signal transducer and activator of transcription 3 activation, generating reactive oxygen species, promoting cell cycle arrest, and activating the caspase pathway. These CDNVs exhibited strong anticancer effects both in vitro and in vivo, and reduced the rate of tumor growth without obvious toxicity to mouse visceral organs. Compared with an equivalent dose of cucurbitacin B, CDNVs exerted stronger anticancer effects in vitro and in vivo. Conclusion These results demonstrate that CDNVs suppress tumor growth. This study addresses the development of cancer therapeutic drugs using plant-derived nanovesicles that are cost-efficient, simple to produce in high yields, and provide an alternative approach to drug isolation that may help advance sustainability of medicinal plants.

show abstract

Section: Anticancer Effects Of Cdnvs In Vitrocontrasting

confidence: 72%

Section: Hplc and Lc-ms For Cub Analysismentioning

confidence: 88%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cucumber-Derived Nanovesicles Containing Cucurbitacin B for Non-Small Cell Lung Cancer Therapy

Chen¹,

Ma²,

Shi³

et al. 2022

IJN

View full text Add to dashboard Cite

show abstract

“…However, as the oral route of administration reflects better patient compliance and are much more feasible in clinical settings relative to systemic injections particularly considering the natural products, hence, there is an impending urgency to find a suitable formulation of CuB that can improve the pharmacokinetic properties and mask the bitter taste in order to translate the pre-clinical outcomes of CuB in human subjects. There have been a few attempts for a safe route for delivery of CuB with greater bioavailability and better patient compliance [54][55][56][57], however, none have targeted brain-specific delivery of CuB.…”

Section: Discussionmentioning

confidence: 99%

Cucurbitacin B exerts neuroprotection in a murine Alzheimer’s disease model by modulating oxidative stress, inflammation, and neurotransmitter levels

Kumar

Kabra

2022

Front. Biosci. (Landmark Ed)

View full text Add to dashboard Cite

Background: Alzheimer's disease (AD) type dementia encompasses diverse cognitive deficits marked by free radicals and proinflammatory cytokines mediated progressive neurodegeneration and vascular damage including the blood-brain barrier. Subsequently, an imbalance in neurotransmitters, excitotoxicity, and synaptic loss provide impetus to AD pathogenesis and perpetuate brain dysfunctions. Cucurbitacin possesses several biological properties and has shown potential in cancer, diabetes, and brain disorders. In this study, neuroprotective effects of cucurbitacin B (CuB) were investigated using the intracerebroventricular streptozotocin (STZ-ICV) AD prototype. Methods: Wistar rats (adult males) were injected STZ-ICV (3 mg/kg) bilaterally on day(s) 1 and 3. Rats were treated with CuB (25, 50 mg/kg, i.p.) or donepezil (1 mg/kg, i.p.) for 28 days daily starting from day 1. Behavioral tests viz. locomotor activity, motor coordination, and memory functions were conducted at different time intervals. After behavioral tests, biochemical markers of oxidative mutilation, inflammatory cell demise, and neurotransmitters were assessed in the whole brain. Results: CuB attenuated STZ-ICV-induced decrease in spatial memory in novel object recognition task and long-term memory in passive avoidance test. CuB diminished protein carbonyls, lipid peroxidation, 8-hydroxy-2'-deoxyguanosine, and enhanced antioxidants in the brain of rats inoculated with STZ-ICV. A decline in inflammatory and cell death biomarkers was observed in rats treated with CuB and STZ-ICV. In neurotransmitter analysis, a decrease in acetylcholinesterase activity and glutamate levels indicated an increase in cholinergic and attenuation of excitatory transmission in the brain. GABA (γ-aminobutyric acid) levels were enhanced by CuB treatment in the STZ-ICV rat model. Histomorphometry analysis disclosed that CuB treatment caused an increase in viable neuron density in the cortex and hippocampus of rats against STZ-ICV neurotoxicity. Conclusions: It can be inferred that CuB can afford a decline in AD symptoms. CuB protects neurons against STZ-ICV toxicity that improved memory functions in rats.

show abstract

“…Lipozom ve polimerik nanopartikül gibi popüler kullanılan nanotaşıyıcılarda görülen bu dezavantajların üstesinden gelmek için araştırmacılar yeni arayışlara yönelmiştir ve bu doğrultuda lipit bazlı nanotaşıyıcılar dikkat çekmiştir. Nanoyapılı lipit taşıyıcılar (NLC), katı lipit nanopartiküller (SLN), lipit-etkin madde konjugatları, lipit nanokapsüller (LNC) ve lipit-polimer hibrit nanopartiküller (LPHN) lipit bazlı nanoboyutlu ilaç taşıyıcı sistemlerin en önde gelen örneklerini oluşturmaktadırlar [16,17,18,19].…”

Section: Introductionunclassified

Yeni̇ Nesi̇l Li̇pi̇t Bazli İlaç Taşiyici Si̇stemler: Li̇pi̇t Nanokapsüller

Demirtaş¹,

Sengel-Türk²

2022

Ankara Universitesi Eczacilik Fakultesi Dergisi

View full text Add to dashboard Cite

Amaç: Nanopartiküler ilaç taşıyıcı sistemler, boyuta bağlı özelliklerinden dolayı giderek artan şekilde ilgi görmektedir. Bu sistemler arasında polimerik nanopartiküller ve lipozomlar en popüler nanotaşıyıcılardandır; ancak bu sistemlerde görülen düşük stabilite, kısa raf ömrü, hazırlanmasında organik çözücü kullanımı, ölçek büyütmenin zor olması gibi dezavantajların üstesinden gelmek için araştırmacılar lipit bazlı nanotaşıyıcılara yönelmiştir. Yeni nesil lipidik taşıyıcılardan olan lipid nanokapsüller (LNC), hidrofilik ve lipofilik sert bir surfaktan kabuk ile çevrelenmiş yağlı sıvı çekirdekten oluşan sistemlerdir ve polimerik nanokapsüller ile lipozomlar arasında yer alan hibrit bir yapıya sahiptirler. Bu derleme kapsamında LNC'ler hakkında genel bilgiler, hazırlama yöntemi ve uygulama yollarına ilişkin bilimsel çalışmalar sunulmuştur.Sonuç ve Tartışma: Tüm bileşenleri FDA onaylı olan LNC'ler, organik çözücü içermeyen, düşük enerji tüketimli ve ölçek büyütmeye elverişli patentli bir üretim teknolojisi olan faz inversiyon yöntemiyle kolayca hazırlanabilmektedir. Bu yöntem ile 20-100 nm partikül büyüklüklerinde ve dar bir dağılım aralığında elde edilen LNC'ler yüksek etkin madde yükleme kapasitesine sahip olmaları, yüzey modifikasyonuna elverişli olmaları, yüzeyindeki polietilen glikol zincirleri sayesinde uzun süre kan dolaşımında kalabilmeleri ve fiziksel stabilitelerinin yüksek olması (18 aya kadar) gibi çok sayıda avantaja sahiptirler. LNC'lerin, lipofilik, amfifilik ve hidrofilik özellikteki pek çok etkin madde için oral, parenteral, topikal, pulmuner yollar gibi çeşitli uygulama yolları kullanılarak farklı farmasötik uygulamalarda kullanılması onların potansiyel ilaç taşıyıcı sistemler olduğunu göstermektedir. Sahip oldukları bu üstün özellikler sayesinde LNC'ler başta lipozomlar ve polimerik nanokapsüller olmak üzere ilaç taşıyıcı sistemlerde gözlenen dezavantajların üstesinden gelerek umut verici alternatif yeni nesil ilaç taşıyıcı sistemler olarak karşımıza çıkmaktadır.

show abstract

Encapsulation of cucurbitacin B into lipid polymer hybrid nanocarriers induced apoptosis of MDAMB231 cells through PARP cleavage

Cited by 31 publications

References 56 publications

Cucumber-Derived Nanovesicles Containing Cucurbitacin B for Non-Small Cell Lung Cancer Therapy

Cucumber-Derived Nanovesicles Containing Cucurbitacin B for Non-Small Cell Lung Cancer Therapy

Cucurbitacin B exerts neuroprotection in a murine Alzheimer’s disease model by modulating oxidative stress, inflammation, and neurotransmitter levels

Yeni̇ Nesi̇l Li̇pi̇t Bazli İlaç Taşiyici Si̇stemler: Li̇pi̇t Nanokapsüller

Contact Info

Product

Resources

About